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S UMMA R Y
S E T T I N G : The global target of tuberculosis (TB)
elimination by 2050 requires new approaches. Active
case finding plus mass prophylactic treatment has been
disappointing. We consider mass full anti-tuberculosis
treatment as an approach to TB elimination in Kiribati,
a Pacific Island nation, with a persistent epidemic of high
TB incidence.
OB J E C T I V E : To construct a mathematical model to
predict whether mass treatment with a full course of
anti-tuberculosis drugs might eliminate TB from the
defined population of the Republic of Kiribati.
METHODS : We constructed a seven-state compartmen-
tal model of the life cycle of Mycobacterium tubercu-
losis in which active TB disease arises from the
progression of infection, reinfection, reactivation and
relapse, while distinguishing infectious from non-infec-
tious disease. We evaluated the effects of 5-yearly mass
treatment using a range of parameter values to generate
outcomes in uncertainty analysis.
R E SU LT S : Assuming population-wide treatment effec-
tiveness for latent tuberculous infection and active TB of
790%, annual TB incidence is expected to fall sharply
at each 5-yearly round of treatment, approaching
elimination in two decades. The model showed that
the incidence rate is sensitive to the relapse rate after
successful treatment of TB.
CONC LU S I ON : Mass treatment may help to eliminate
TB, at least for discrete or geographically isolated
populations.
K E Y WORD S : mass treatment; tuberculosis; elimina-
tion
THE ELIMINATION of tuberculosis (TB) at the
global level by 2050 is an internationally agreed
target.1 Elimination has been defined as an annual
incidence rate of ,1 new TB case per 1 000 000
population, a rate expected to prevent sustained
transmission of Mycobacterium tuberculosis.2,3
However, TB elimination is clearly unrealistic with-
out new tools and approaches.4 One thing is clear: a
combined, simultaneous attack on active disease and
latent tuberculous infection (LTBI) will be neces-
sary.2,4
Active case finding plus mass prophylactic treat-
ment against LTBI was evaluated by Comstock et al.
among Alaskan Inuits in the 1960s. In a formal trial,
97% of individuals aged .2 months were rando-
mised by household to receive 12 months of isoniazid
(INH) prophylaxis or placebo, after screening with
chest radiography to identify and treat those with
active TB.5 Over a median 69 months of follow-up,
141 TB cases were diagnosed in the placebo arm (n¼
3017; crude incidence rate [IR] 812/100 000/year)
and 58 in the INH arm (n ¼ 3047; IR 331/100 000/
year). Mass prophylactic treatment in the placebo
arm subsequently resulted in further reductions, but
not elimination, of incident TB cases over 19 years of
follow-up.6,7 Horwitz et al. conducted a similar trial
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of mass prophylactic treatment along with active case
finding in Greenland, in which 92% of eligible
subjects participated.8 Adults in 76 paired villages
were assigned, by village, to 6 months of INH
prophylaxis (n ¼ 3907) or placebo (n ¼ 4174), after
being medically assessed for TB disease. Over 6 years
of active follow-up, there were 238 cases (IR 1015/
100 000/year) in the INH arm and 323 cases (IR
1289/100 000/year) in the placebo arm.
It is important to ask why active case finding plus
mass prophylactic treatment was so unsuccessful with
respect to TB elimination. One strong possibility is
that individuals with active TB disease were initially
missed due to limitations in diagnostic procedures.
An alternative mass treatment strategy that may
overcome this limitation is the administration of a
treatment regimen for TB disease to the whole
population.
We aimed to assess whether such a strategy could
lead to TB elimination in the well-defined, isolated
population of Kiribati in the Pacific, where mass
prophylactic treatment for leprosy has been under-
taken previously with high rates of community
participation.9
METHODS
Strategy and rationale
In this approach, a full course of anti-tuberculosis
treatment is given to everyone: those with active
disease (diagnosed and undiagnosed), those with
LTBI and those who are not infected with M.
tuberculosis. The rationale is as follows: all those
with active, drug-susceptible disease will be treated
and rendered non-infectious rapidly, those with drug-
susceptible LTBI will have all residual tubercle bacilli
killed, and those without infection will be prevented
from getting infected at least while on treatment.
Setting
The Republic of Kiribati comprises 35 atolls and one
raised coral island spread across 3.5 million km2 in
the central tropical Pacific. Almost half of the
population of approximately 100 000 people lives in
one urban area, South Tarawa. Kiribati is one of the
poorest and least developed countries in the Pacific
and is heavily reliant on external sources of income. It
has a TB epidemic, with an annual case notification
rate of approximately 335 new TB cases/100 000/
year since the mid-1990s (Figure 1A). Kiribati has a
young population (Figure 1B), and the age group 15–
24 years has the largest number of cases (Figure 1C).
The equally high rates of TB incidence among adults
of all ages are indicative of ongoing transmission
(Figure 1D). In a recent (2011) survey of a represen-
tative sample of 394 adults (aged .18 years), 45%
were tuberculin skin test positive, with a peak of 66%
in those aged 45–54 years (unpublished data). The
rate of increase in the percentage positive by age
suggests an average annual risk of infection of about
Figure 1 A) Total number of TB cases reported, Kiribati, 1995–2012; B) distribution of population by age; C) reported male and
female TB cases by age; D) total TB case rates by age. TB¼ tuberculosis.
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2% over the past 50 years. Current TB control efforts
include 6-month directly observed chemotherapy for
TB cases, contact tracing, INH prophylaxis for
contacts aged ,5 years and those with diabetes,
and screening of community members for TB in
identified ‘hotspots’. Although no representative
surveys have been conducted, fewer than 100 human
immunodeficiency virus positive individuals have
ever been identified. Only one case of multidrug-
resistant TB (i.e., resistance to at least INH and
rifampicin [RMP]) has been diagnosed, and fewer
than 10 cases with monoresistance have been found
(unpublished National Tuberculosis Control Pro-
gramme [NTP] data).
As this study used routinely available data, ethical
permission was not required.
Model
To determine the effects of mass treatment in Kiribati,
we constructed a compartmental model of the life
cycle of M. tuberculosis in which active TB disease,
both infectious and non-infectious, arises from the
progression of infection, reinfection, reactivation and
relapse.4 Figure 2 shows the seven exclusive states
included in the closed model (no migration). The
corresponding set of coupled non-linear difference
equations and model parameter values based on
previous similar analyses4 are shown in the Appen-
dix.*
Using the solver function in Microsoft Excel
(Microsoft, Redmond, WA, USA), we fitted the
model to the series of annual case reports from
Kiribati (Figure 1A) by varying the contact rate b,
assuming that TB was stably endemic before any
further intervention, at an average of 330 cases/
100 000 reported between 2000 and 2012. With the
point estimates given in Appendix Table A, the basic
case reproduction number of TB in Kiribati is R0 ¼
4.3 and the annual risk of infection in the steady state
is approximately 3%.
To improve the effective treatment of active
disease, we increased the rate of transfer of infectious
and non-infectious TB cases to the cured state. The
rate of transfer is determined by the product of the
case detection rate and the proportion cured. Cases
who are detected but not cured remain cases of active
disease. To represent periodic rounds of mass
treatment of the population in the model, a propor-
tion p of people (0.6, 0.8, 0.9 or 0.95) in each of the
classes Lf and Ls are moved instantly, at 5-year
intervals, to ‘treated latent’ class Cl. At the same time,
a proportion p of I and N are moved to ‘cured’ class
Cd, with a chance of relapse back to I and N. To
replicate the protective effect of treating non-infected
people, U, the contact rate b between I and U was
scaled down to b(1r) for the 6-month duration of
treatment, after which it reverts to b. Control variable
p, our measure of effectiveness, is the product of
population coverage and treatment efficacy per
capita.
To investigate the factors responsible for uncer-
tainty in outcomes, we generated 1000 Latin hyper-
cube samples with a Mersenne twister (Palisade
@Risk software; Palisade Corp, Ithaca, NY, USA)
along a uniform distribution between low and high
parameter values (Appendix Table A). The impor-
tance of each model parameter was measured by the
correlation between values of that parameter and
values of the primary outcome measure, the TB
incidence rate in 2050.
RESULTS
Routine TB control
TB control as currently practised by the NTP is
represented by a detection rate of cases I andN of 0.4/
year, so that the proportion of cases ever detected is
0.58, with the proportion of cases cured set at 0.8.
Under these circumstances, the average duration of
an infectious TB case is 1.5 years. To illustrate an
improvement in routine TB control, the case detec-
tion rate is increased to 1.9/year (0.96 of all cases ever
detected) and the proportion cured increased to 0.85.
This reduces the average duration of an infectious
case threefold, from 1.5 years to 0.5 years. This has
the effect of forcing down the TB incidence rate at an
average of 10% per year over the 10 years from 2015
to 2024, to around 100/100 000 population by 2035
(Figure 3, line 3). To reduce the incidence by a factor
of three in 20 years is significant progress. However, it
is clear that no level of improvement to routine TB
Figure 2 Flow chart of the compartmental mathematical
model showing seven states, and the transitions in and out of
each state in a closed population (no migration).
*The Appendix is available in the online version of this article,
at http://www.ingentaconnect.com/content/iuatld/ijtld/2014/
00000018/00000008/art00005
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control could eliminate TB in Kiribati within the
space of a few decades. An alternative way to reduce
incidence is by mass periodic treatment of active TB.
However, a strategy of curing 0.9 of all TB cases every
5 years would be less successful than improving
routine control in the example above (Figure 3,
compare lines 2 and 3).
Periodic mass treatment of the whole population
In the calculations illustrated in Figure 3, we explored
the effects of r ¼ 0.6, 0.8, 0.9 and 0.95. With a
treatment effectiveness of r¼0.9 for LTBI and active
TB, and the same proportion of non-infected people
protected against infection, the annual TB incidence
is expected to drop precipitously at each 5-yearly
round of treatment, falling to the elimination
threshold within two decades (by 2035, Figure 3,
line 5). Improving treatment effectiveness to 0.95
would lead to elimination by 2030. The lowest
possible incidence rate to which lines converge is
governed by the incidence of relapse after successful
treatment of active TB.
Uncertainty analysis
The results of the sensitivity analysis of TB incidence
rate in 2050 to each of the model parameters, where
sensitivity is measured by the correlation coefficient,
are presented in Appendix Figure A. The relapse rate
after treatment of active TB is by far the most
important determinant of TB incidence rate in 2050.
With a per capita relapse rate higher than 105 per
year, it would not be possible to eliminate TB by
2050. However, irrespective of whether or not the
elimination threshold is reached, the analysis is
robust to our main conclusion: periodic mass
treatment is a far more effective way of reducing TB
incidence than the routine treatment of active disease.
DISCUSSION
In this paper, we have used mathematical modelling
to investigate whether mass treatment with a full
course of anti-tuberculosis drugs could eliminate TB
from what might be considered an ideal target
population — a Pacific island nation with a poorly
controlled TB epidemic. Assuming a high level of
mass treatment effectiveness for LTBI and active TB
(r 7 0.9) and protection of non-infected people, the
annual TB incidence is expected to fall precipitously
at each 5-yearly round of treatment, approaching
elimination in two decades.
We have obtained this result with a simple
compartmental model of TB epidemiology. We do
not therefore claim to make precise forecasts of when
elimination could be achieved in Kiribati. For
example, the lowest achievable incidence rate within
the next few decades is sensitive to the relapse rate
after treatment of active TB, which is not accurately
known. It is exposed by this study as a crucial factor
in TB elimination. The uncertainty surrounding these
details does not detract from the key point of our
analysis, which is that mass population treatment is a
far more effective intervention than routine treatment
of active TB. We do not propose that the former
should replace the latter, but rather that mass
treatment would be a powerful supplementary
measure to cut TB incidence to a minimum within
2–3 decades.
A number of issues require careful consideration
(Table) beyond a formal cost analysis, which is
outside of the scope of this paper. First, shorter
regimens could be considered. Those with LTBI are
likely to be successfully treated after 3 months of a
regimen that includes both RMP and INH.10 While
relapse rates are lowest with 6 months of treatment,
they are almost as low with regimens as short as 3
months’ duration.11 Indeed, studies could address
whether those with occult, asymptomatic disease
could be safely treated with less than 6 months of
treatment. It is also anticipated that new drug
regimens for all TB disease will be shorter in the
future and have fewer side effects.12
Second, the main concern with respect to the side
effects of treatment is hepatotoxicity. Interpretation
of the available data is complicated by a disconnect
between biochemical indices and clinical manifesta-
tions of hepatotoxicity,13 the lack of a standardised
approach to diagnosis and management, and huge
variations in the reported risk.14 Reassuringly, a study
of 752 Danish patients on anti-tuberculosis treatment
showed that the drugs could be continued, or
successfully reintroduced in full, in most patients in
whom liver enzyme levels increased up to six times
Figure 3 Expected reductions in TB incidence in Kiribati in
response to five treatment scenarios. The black dots mark
reported TB cases. Numbered lines represent: 1) continuation of
the current strategy in which 0.58 of all cases are detected and
0.8 cured, 2) 5-yearly mass treatment of active TB only, with 0.9
effectiveness, 3) improved routine treatment of active TB by the
national TB control programme, raising the proportion detected
to 0.96 and the proportion cured to 0.85, 4–7) mass treatment
of the population with effectiveness of r ¼ 0.6, 0.8, 0.9 and
0.95, respectively. TB¼ tuberculosis.
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the upper limit of normal.15 Additional reassurance is
provided from resource-poor countries, where the
bulk of anti-tuberculosis treatment is provided
without routine biochemical testing — there have
not been large numbers of reported cases of fatal
drug-induced hepatitis.
Third, consideration could be given to excluding
certain groups from treatment. In their trial, Com-
stock et al. excluded children aged ,2 months who
had no known TB contact.5 Other groups that could
also be considered for exclusion are shown in the
Table.
Fourth, a comprehensive public health approach
would be required. Standardised surveillance of
active disease would be necessary before and after
the intervention, and appropriate processes would be
required for dealing with data. The project would
also require public education and engagement,
adequate finances and staff, overall project manage-
ment, and reliable and timely monitoring, evaluation
and reporting. Elimination from an island would only
be theoretically possible if, after the whole population
has received treatment, they are no longer exposed to
M. tuberculosis. Those persons who travel back and
forth to the islands (e.g., for trade, education, etc.)
and new immigrants would therefore need to be
considered for treatment.
Fifth, there are important ethical principles to
consider with any mass treatment strategy.16 Major
issues include how to weigh population benefit
against the lack of guaranteed benefit to any single
individual and the potential to cause harm, how to
engage in a sustained manner with the community
and how to avoid coercion, which can be difficult to
differentiate from persuasion in the context of a
public health promotion and education campaign
required for the project.
Mass treatment of the population for TB would
have other non-TB benefits. For example, RMP is an
effective prophylactic agent against leprosy, which
remains endemic in many Pacific countries, presum-
ably through clearance of nasal carriage.17 As
mentioned above, mass prophylactic treatment for
leprosy was undertaken in Kiribati in the 1990s, with
very high rates of community participation of over
90%.9
Providing anti-tuberculosis treatment to the whole
population could in theory eliminate TB in an island
nation such as Kiribati, without any other public
health actions and without improved diagnostic tests.
Sub-total coverage and the potential for future
relapse with current anti-tuberculosis treatment
implies that more than one round of treatment is
required. While there are a number of issues that need
to be considered, this approach is likely to become
more feasible with the availability of more effective,
shorter and safer drug regimens. In anticipation of
this, a number of preliminary studies could be
conducted specifically to facilitate such an approach.
A Pacific Island nation such as Kiribati has great
potential to host preparatory studies with a view to a
mass treatment approach in the future.
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APPENDIX
The different equations describing the dynamics of
the seven health states in Figure 1 are as follows. The
notation implies, for uninfected people, that Utþ1 ¼
f(Ut, It, Nt), etc., for each of the seven states. The
subscripts denoting time (t, tþ1) are dropped for
clarity. Definitions of parameters are shown in Table
A. This compartmental model describes the baseline
epidemiology of TB, before introducing the further
interventions described in the main text.
Uninfected (U)
¼ U þ ðbIU  lU þ lþ ltI þ lnNÞdt
Fast latent (Lf)
¼ Lf þ ðbpIU  ðlþ tf ÞLf Þdt
Slow latent (Ls)
¼ Ls þ ðbð1 pÞIU  ðlþ vsÞLs  bpxILs þ x¯lClÞdt
Infectious TB (I)
¼ I þ ðsmf Lf þ smsLs  ðlþ lt þ gþ skÞI
þ bpxsILs þ sðx¯d þ bpxIÞCÞdt
Non-infectious TB (N)
¼ N þ ðð1 sÞmf Lf þ ð1 sÞmsLs
 ðlþ ln þ gþ skÞN þ bpxð1 sÞILs
þ ð1 sÞðx¯d þ bpxIÞCÞdt
Active TB treated with drugs (Cd)
¼ Cd þ ððgþ skÞðI þNÞ  ðlþ x¯dÞCd  bpxICdÞdt
The final state, consisting of people with latent
tuberculous infection who have been successfully
treated (Cl), is created only by periodic mass
treatment of Lf and Ls, as described in the main text.
The rate of loss from this compartment is[(lþ x¯l)Cl
þ bpxICl]dt.
The basic case reproduction number of this system
is as follows:
R0 ¼ bs
pvf
lþ vf
þ ð1 pÞvs
lþ vs
 
c
lþ lt þ gþ sj
where c is the average number of episodes of
infectious TB suffered by each case, allowing for
relapse from natural cure and from cure following
drug treatment. The proportion of infectious cases
that goes through one cycle of cure and relapse is:
c0 ¼ ðgþ sjÞx¯dðlþ lt þ gþ sjÞðlþ x¯dÞ
Therefore, the total number of cycles or episodes is
c¼ 1/(1 c).
Figure A Sensitivity analysis of TB incidence rate in 2050 to
each of the model parameters (see Table A), where sensitivity is
measured by the correlation coefficient.
Table A Model parameter values and their definitions
Parameter value Point Low High Source
Time step, year dt 0.1 Chosen to be short relative to
duration of other
epidemiological and population
processes
Contact rate between infectious cases and others, /year b 14.8 13.3 16.2 Fitted to generate initial incidence
rate 330/100000/year
Proportion infections becoming fast latent p 0.15 0.13 0.17 1
Rate of progression from latent to active TB, fast, /year vf 0.67 0.60 0.73 2
Rate of progression from latent to active TB, slow, /year vs 0.0020 0.0010 0.0030 1,3,4
Death rate, not TB, /year l 0.02 0.018 0.022 Based on 50 years of expected life
from age 18 (data.un.org)
Death rate infectious TB, /year lt 0.15 0.10 0.20 Fitted to generate a case fatality of
0.23 overall, and initial TB
mortality rate 50/100000/year
Death rate non-infectious TB, /year ln 0.06 0.030 0.090
Natural cure rate all forms of TB, /year g 0.20 0.15 0.25 1
Proportion incident TB cases that is infectious s 0.45 0.35 0.55 1
Proportion of reinfections that lead to active TB x 0.20 0.10 0.30 1,5
Relapse rate after cure of active TB, /year pd 1e05 0eþ00 2e05 Baseline estimate adjusted in
sensitivity analysis
Relapse rate after treatment of latent TB, /year pl 0 0 0 Assumed
TB¼ tuberculosis.
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R E S UM E
CONT E X T E : L’objectif mondial d’e´limination de la
tuberculose (TB) d’ici 2050 requiert de nouvelles
approches. La recherche active des cas et le traitement
pre´ventif de masse ont e´te´ de´cevants. Nous envisageons
le traitement anti-tuberculeux de masse complet comme
une approche possible de l’e´limination de la TB a`
Kiribati, une des ıˆles du Pacifique ou` persiste une
e´pide´mie de TB a` incidence e´leve´e.
OB J E C T I F : Construire un mode`le mathe´matique afin
de pre´dire si le traitement de masse complet par
me´dicaments antituberculeux serait susceptible
d’e´liminer la TB de la population de la Re´publique de
Kiribati.
M E´ T H O D E S : Nous avons construit un mode`le
compartimental en sept e´tats du cycle de vie de
Mycobacterium tuberculosis dans lequel la maladie
tuberculeuse active re´sulte de la progression de
l’infection, de la re´infection, de la re´activation et de la
rechute, tout en distinguant la forme contagieuse et non
contagieuse. Nous avons e´value´ les effets d’un traitement
de masse tous les 5 ans, en utilisant une se´rie de valeurs
de parame`tres afin de ge´ne´rer des re´sultats d’analyse
d’incertitude.
R E´ S U LTAT S : En estimant a` 790% l’efficacite´ du
traitement de toute une population pour une infection
tuberculeuse latente et une TB active, l’incidence
annuelle de la TB devrait chuter brutalement lors de
chaque traitement de masse tous les 5 ans, arrivant a`
l’e´limination en deux de´cennies. Le mode`le a montre´ que
l’incidence e´tait sensible a` la rechute apre`s un traitement
re´ussi de la TB.
C O N C L U S I O N : Le traitement de masse pourrait
contribuer a` e´liminer la TB, au moins dans des
populations distinctes ou ge´ographiquement isole´es.
R E S UM E N
MA R C O D E R E F E R E N C I A: La meta mundial de
eliminacio´n de la tuberculosis (TB) en el 2050 exige
nuevos enfoques. Los resultados de la bu´squeda activa
de casos aunada al tratamiento profila´ctico colectivo
han sido decepcionantes. Se propone el tratamiento
antituberculoso completo colectivo como estrategia de
eliminacio´n en Kiribati, una isla del Pacı´fico con una
epidemia de TB persistente de alta incidencia.
O B J E T I V O: Construir un modelo matema´tico que
permitiese predecir si un plan colectivo de tratamiento
antituberculoso completo podrı´a eliminar la TB en una
poblacio´n definida de la repu´blica de Kiribati.
M E´ TODOS: Se construyo´ un modelo compartimental de
siete estados clı´nicos de la infeccio´n por Mycobacterium
tuberculosis, en el cual la enfermedad activa surge de la
progresio´n de la infeccio´n, la reinfeccio´n, la reactivacio´n
o la recaı´da, distinguiendo la enfermedad contagiosa de
la enfermedad no contagiosa. Mediante un ana´lisis de
incertidumbre se evaluaron los efectos de 5 an˜os de
tratamiento colectivo, al aplicar una serie de para´metros
con el fin de generar desenlaces clı´nicos.
R E SU LTADOS: En la hipo´tesis de que la eficacia de un
tratamiento a escala poblacional de la infeccio´n
tuberculosa latente y de la enfermedad activa es
790%, se preve´ que la incidencia anual de TB
disminuya de manera pronunciada en cada ronda de 5
an˜os de tratamiento y se llegue cerca de la eliminacio´n en
dos decenios de aplicacio´n. El modelo puso en evidencia
que la tasa de incidencia es sensible a la tasa de recaı´da
despue´s de un tratamiento antituberculoso eficaz.
C O N C L U S I O´ N: El tratamiento colectivo podrı´a
contribuir a eliminar la TB, por lo menos en
poblaciones definidas o geogra´ficamente aisladas.
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